Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 39,800 shares, a growth of 22.1% from the January 31st total of 32,600 shares. Based on an average daily volume of 14,100 shares, the days-to-cover ratio is presently 2.8 days. Currently, 0.5% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $9.00 price objective on shares of Prenetics Global in a research note on Thursday, January 16th.

Institutional Trading of Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new stake in Prenetics Global Limited (NASDAQ:PRE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent reporting period. 25.01% of the stock is owned by hedge funds and other institutional investors.

Prenetics Global Price Performance

Shares of NASDAQ:PRE opened at $4.81 on Thursday. The company has a market capitalization of $58.65 million, a price-to-earnings ratio of -1.20 and a beta of -0.31. The business’s 50-day moving average is $5.51 and its 200-day moving average is $5.01. Prenetics Global has a 1 year low of $2.85 and a 1 year high of $7.84.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.